Core Insights - Gilead Sciences, Inc. (NASDAQ:GILD) is highlighted as a significant stock within the Renaissance Technologies Portfolio [1] - JPMorgan analyst Chris Schott raised the price target for Gilead from $135 to $145, maintaining an Overweight rating [2] - The adjustment indicates a 29% upside potential for Gilead from its closing share price on September 22 [2] - Wall Street analysts generally hold a positive outlook on Gilead, with a consensus Buy rating [2] Company Overview - Gilead Sciences, Inc. is a biopharmaceutical company focused on developing medicines for life-threatening diseases such as HIV, viral hepatitis, and cancer [3]

Core Viewpoint - Gilead Sciences, Inc. (GILD) is initiated with a Strong Buy rating and a price target of $181, focusing on its transformative therapies in HIV, viral hepatitis, oncology, and other unmet medical needs globally [1]. Group 1: Company Overview - Gilead is engaged in the discovery, development, and commercialization of therapies that address significant medical needs [1]. - The company operates in various therapeutic areas, including HIV, viral hepatitis, and oncology, indicating a diversified portfolio [1]. Group 2: Research Methodology - Moretus Research employs a structured, repeatable framework to identify companies with durable business models and mispriced cash flow potential [1]. - The research emphasizes rigorous fundamental analysis combined with a judgment-driven process, focusing on clarity and actionable insights [1]. - Valuation methods are based on sector-relevant multiples tailored to each company's business model, ensuring comparability and relevance [1]. Group 3: Investment Philosophy - Moretus Research targets underappreciated companies undergoing structural changes or temporary dislocations, where disciplined analysis can yield asymmetric returns [1]. - The research aims to elevate the standard for independent investment research by providing professional-grade insights and a strong filter for essential information in equity analysis [1].